

MBS Antibigram 2025

GRAM NEGATIVE		ANTIBIOTICS														
1/1/2025-12/31/2025	Number tested	Amoxicillin/Clavulanic Acid	Ampicillin	Cefazolin	Cefepime	Ceftriaxone	Ciprofloxacin	Ertapenem	Gentamicin ^(b)	Levofloxacin	Meropenem	Nitrofurantoin ^(c)	Piperacillin/Tazobactam	Tetracycline	Tobramycin	Trimeth/Sulfa
ORGANISM	PERCENT SUSCEPTIBLE															
<i>Escherichia coli</i>	635	85		86	95	91	71	#	90	72	100	98	97			74
<i>Klebsiella pneumoniae</i>	86	94		84	93	93	87	#	95	90	100	31	91			88
<i>Proteus mirabilis</i>	76	80		84	91	84	57	#	86	57	100	0	100			66
<i>Pseudomonas aeruginosa</i>	108				100		81			79	89		80			

GRAM POSITIVE		ANTIBIOTICS										
1/1/2025-12/31/2025	Number tested	Ampicillin	Clindamycin	Erythromycin	Gentamycin (High-Level)	Linezolid	Nitrofurantoin ^(c)	Oxacillin	Streptomycin (High-Level)	Tetracycline	Trimeth/Sulfa	Vancomycin
Organism	PERCENT SUSCEPTIBLE											
<i>Enterococcus faecalis</i>	80	100		11	82	96	99		94	25		100
<i>Staphylococcus aureus</i> , ALL	232		66	36		100		46		75	78	100
MRSA only	120		61	18		100		0		68	56	100
MSSA only	112		71	52		100		100		88	96	100
<i>Staphylococcus epidermidis</i>	40		58	30		100		43		73	35	100

	85-100% Susceptible
	60-84% Susceptible
	<60% Susceptible
#	Not routinely tested. Historical data suggests frequent susceptibility; confirm with microbiology when relevant
•	Due to the presence of inducible beta-lactamases, this organism should be considered resistant to the antimicrobial indicated
	Shaded boxes indicate organism/antimicrobial combines not tested routinely

(a) Data with fewer than 30 isolates has poor statistical validity.

(b) Aminoglycoside breakpoints were lowered in 2023 for Enterobacterales and *Pseudomonas aeruginosa*. Gentamicin should no longer be used for the treatment of *Pseudomonas aeruginosa* infections.

(c) Nitrofurantoin should only be used for infections localized to the bladder only.